{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:55:54Z","timestamp":1790751354210,"version":"4.1.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Distinguishing a left ventricular thrombus from a cardiac tumor is challenging when a large mass arises at an atypical non-apical site, particularly in a patient with cancer. We describe a 37-year-old man with epidermal growth factor receptor-mutant non-small cell lung cancer receiving almonertinib who developed a broad-based posterior wall left ventricular mass while cancer imaging remained stable. At detection, the reported left ventricular ejection fraction estimate was 55%, and no regional wall motion abnormality was documented. Cardiac CT showed no calcification or appreciable arterial- or delayed-phase enhancement, and Doppler echocardiography showed no internal flow. Low-mechanical-index contrast-enhanced echocardiography showed no appreciable internal perfusion in the contemporaneous examination report; later archived images also showed persistent absence of perfusion, although early-phase cine loops were not retained for retrospective reassessment. These concordant avascular features supported the presence of a thrombus but were not diagnostic. Cardiac magnetic resonance was recommended but declined because of financial concerns, and histopathology was unavailable. After approximately 9 months of prescribed edoxaban 60\u2005mg once daily with reported adherence, the maximum linear dimension increased from 39.7 to 51.0\u2005mm. A posterior wall regional wall motion abnormality was first documented 5 months after mass detection and therefore could not explain the lesion already present at detection. Edoxaban levels and edoxaban-calibrated anti-factor Xa activity were not measured, and human interaction data for almonertinib and edoxaban were unavailable. This case highlights the need to keep the diagnosis qualified and to reassess alternative pathology and anticoagulant exposure when an imaging-supported left ventricular thrombus follows an unexpected course.<\/jats:p>","DOI":"10.3389\/fcvm.2026.1953416","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:04:45Z","timestamp":1790748285000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: An enlarging left ventricular mass during anticoagulation in a patient receiving almonertinib after thoracic radiotherapy: diagnostic uncertainty and individualized management"],"prefix":"10.3389","volume":"13","author":[{"given":"Bin","family":"He","sequence":"first","affiliation":[{"name":"Department of Oncology and Radiotherapy, Chengdu Qingbaijiang District People\u2019s Hospital","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Tan","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, Chengdu Medical College","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyuan","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Oncology, General Hospital of Western Theater Command, People\u2019s Liberation Army","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, General Hospital of Western Theater Command, People\u2019s Liberation Army","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, General Hospital of Western Theater Command, People\u2019s Liberation Army","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1200\/JCO.21.02641","article-title":"AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations","volume":"40","author":"Lu","year":"2022","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1200\/JCO.20.01171","article-title":"Cardiac safety of osimertinib: a review of data","volume":"39","author":"Ewer","year":"2021","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jtho.2021.10.024","article-title":"Efficacy of aumolertinib (HS-10296) in patients with advanced EGFR T790M-positive NSCLC: updated post-national medical products administration approval results from the APOLLO registrational trial","volume":"17","author":"Lu","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1161\/CIR.0000000000001092","article-title":"Management of patients at risk for and with left ventricular thrombus: a scientific statement from the American Heart Association","volume":"146","author":"Levine","year":"2022","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jaccao.2024.09.006","article-title":"Multimodality imaging in the diagnostic work-up of patients with cardiac masses: JACC: CardioOncology state-of-the-art review","volume":"6","author":"Angeli","year":"2024","journal-title":"JACC CardioOncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e003542","DOI":"10.1136\/openhrt-2025-003542","article-title":"Efficacy and safety of direct oral anticoagulants versus warfarin in patients with a left ventricular thrombus: an updated systematic review and meta-analysis of randomised controlled trials","volume":"12","author":"Costa","year":"2025","journal-title":"Open Heart"},{"key":"B8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming eighth edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12872-024-03708-2","article-title":"The usefulness of contrast echocardiography in the evaluation of cardiac masses: a multicenter study","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"key":"B10","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.amjms.2021.01.014","article-title":"Patients with left ventricular thrombus despite normal systolic function","volume":"362","author":"Svendsen","year":"2021","journal-title":"Am J Med Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"ytag101","DOI":"10.1093\/ehjcr\/ytag101","article-title":"Acute coronary syndrome due to intermittent right coronary artery obstruction by an ascending aortic thrombus in a cancer patient: a case report","volume":"10","author":"Y\u0131lmaz","year":"2026","journal-title":"Eur Heart J Case Rep"},{"key":"B12","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jaccao.2021.06.003","article-title":"Cardiovascular manifestations from therapeutic radiation: a multidisciplinary expert consensus statement from the international cardio-oncology society","volume":"3","author":"Mitchell","year":"2021","journal-title":"JACC CardioOncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","article-title":"Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1001\/jamaoncol.2020.6332","article-title":"Association of left anterior descending coronary artery radiation dose with major adverse cardiac events and mortality in patients with non-small cell lung cancer","volume":"7","author":"Atkins","year":"2021","journal-title":"JAMA Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3109\/02841860903524396","article-title":"Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials","volume":"49","author":"Ranpura","year":"2010","journal-title":"Acta Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/s41401-021-00710-8","article-title":"Itraconazole and rifampicin, as CYP3A modulators but not P-gp modulators, affect the pharmacokinetics of almonertinib and active metabolite HAS-719 in healthy volunteers","volume":"43","author":"Liu","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1111\/bcp.13092","article-title":"Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine","volume":"82","author":"Parasrampuria","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1263975","DOI":"10.3389\/fphar.2023.1263975","article-title":"In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban","volume":"14","author":"Wang","year":"2023","journal-title":"Front Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/bjh.17470","article-title":"A universal anti-Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation","volume":"193","author":"Willekens","year":"2021","journal-title":"Br J Haematol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.jacc.2020.01.057","article-title":"Antithrombotic therapy for patients with left ventricular mural thrombus","volume":"75","author":"Lattuca","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1093\/ehjci\/jeaf156","article-title":"Resolution of left ventricular thrombus assessed by echocardiography: insights from a contemporary multicentre prospective registry","volume":"26","author":"Barbieri","year":"2025","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1161\/CIR.0000000000001174","article-title":"Cardiovascular imaging in contemporary cardio-oncology: a scientific statement from the American Heart Association","volume":"148","author":"Addison","year":"2023","journal-title":"Circulation"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association, the European Society for Therapeutic Radiology and Oncology, and the International Cardio-oncology Society","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1953416\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:04:48Z","timestamp":1790748288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1953416\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":23,"alternative-id":["10.3389\/fcvm.2026.1953416"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1953416","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"article-number":"1953416"}}